e Several viruses, including human papillomaviruses, depend on endosomal acidification for successful infection. Hence, the multisubunit enzyme vacuolar ATPase (V-ATPase), which is mainly responsible for endosome acidification in the cell, represents an attractive target for antiviral strategies. In the present study, we show that V-ATPase is required for human papillomavirus (HPV) infection and that uncoating/disassembly but not endocytosis is affected by V-ATPase inhibition. The infection inhibitory potencies of saliphenylhalamide, a proven V-ATPase inhibitor, and its derivatives, as well as those of other V-ATPase inhibitors, were analyzed on different HPV types in relevant cell lines. Variation in the selectivity indices among V-ATPase inhibitors was high, while variation for the same inhibitor against different HPV subtypes was low, indicating that broad-spectrum anti-HPV activity can be provided.
the manufacturer's instructions. Given the combination of ease of handling and a significant pseudovirion (PsV) infectivity readout, we chose HeLa cells for the initial V-ATPase inhibitor/HPV infectivity screens. The infectivity inhibition by the most potent inhibitors was then reproduced in the more relevant cell line HaCaT and, finally, in primary keratinocytes.
HPV pseudovirions. HPV pseudovirions were prepared as previously described (25) . Briefly, expression plasmids carrying codon-optimized HPV L1 and L2 cDNA were cotransfected with a pCMV-GLuc control (New England Bioscience, United States) or pcDNA3.1/luciferase reporter plasmid into 293TT cells (26) . Forty-eight hours posttransfection, the cells were processed by lysis and nuclease digestion. After maturation, the pseudovirions were purified from the cell lysates by Optiprep gradient centrifugation. Codon-optimized L1 and L2 expression vectors for HPV16, HPV6, and HPV11 were kindly provided by Martin Müller, Heidelberg, Germany, for HPV18 by Chris Buck, Bethesda, MD, and for HPV31 by Tadahito Kanda, Tokyo, Japan (27) (28) (29) (30) (31) .
V-ATPase inhibitors. Inhibitors of the salicylihalamide type were synthesized in the laboratory of J. K. De Brabander (32) (33) (34) (35) 44) . If common names for inhibitors were unavailable, internal laboratory nomenclature was used to refer to the specific substance. ApiA, ApiOpen, PalmA, and decarbamoylated PalmA were from the laboratory of Martin E. Maier. The control compound 543229 was obtained from Hit2Lead, United States.
siRNA experiments. Transfections of HeLa cells were performed with RNAiMAX (Invitrogen) and 30 nM small interfering RNA (siRNA) according to the manufacturer's recommendations. Subsequent experiments (infectivity assays, Western blotting) were done 48 h after siRNA transfection, as we observed that this was the time point of maximal knockdown by siRNA. siRNAs targeting the V-ATPase subunit D1 (ATP6V0D1) and the Allstars negative-control siRNA were purchased from Qiagen. The ATP6V0D1 siRNA target sequences were as follows: siNRA 1, CTGGCTCGGGCTGACGACTAT; siNRA 2, TTACAGTTACA TGATCGACAA; siNRA 3, CAAGAACGTGGCCGATTACTA; and siNRA 4, CTACCTGGAGTCCTTCTACAA.
Knockdown of ATP6V0D1 was confirmed 48 h after siRNA transfection by Western blotting using a specific monoclonal antibody (sc-81887; Santa Cruz). Tubulin was probed as a loading control, using the monoclonal antibody B-5-1-2 (Sigma-Aldrich).
Infectivity assays. Cells were infected with approximately 1,000 pseudovirions per cell. For reverse infections, cells were trypsinized, resuspended in medium, infected in suspension, and seeded on culture plates. ATP6V0D1 siRNA transfections were done 48 h before infection, while V-ATPase inhibitors were added to the cells immediately after infection. Infectivity rates were assessed 24 to 48 h postinfection (p.i.). Experiments were conducted in triplicates. Infectivity assays with the firefly luciferase reporter plasmid were quantified using the cell culture lysis reagent and luciferase assay system (Promega); Infectivity assays with the Gaussia luciferase reporter plasmid were performed in the cell culture supernatant using the Gaussia Juice kit (PJK). Measurements were done with the Tristar LB 941 luminometer (Berthold Technologies).
Cell viability and cytotoxicity. The potential cytotoxicities of inhibitors and siRNAs were assessed with an XTT cell proliferation kit (AppliChem) according to the manufacturer's instructions. The same culture conditions and treatment parameters were used for infectivity and XTT viability/cytotoxicity assays. Determination of CC 50 by XTT in HeLa cells was done after 5 days of incubation with inhibitors. The infectivity values in siRNA assays were normalized by the XTT measurements.
Disassembly/uncoating analysis by immunofluorescence. HeLa cells were grown on glass coverslips and infected either after siRNA transfection or prior to inhibitor addition. At various time points after infection as indicated below, cells were washed with phosphate-buffered saline (PBS) and fixed/permeabilized with methanol (Ϫ20°C). Fixed cells were washed and blocked with 1% bovine serum albumin (BSA)-PBS. Coverslips were incubated for 1 h at 37°C with primary antibodies (indicated below) diluted in BSA-PBS and then washed and blocked with BSA-PBS. Incubation with secondary, Alexa Fluor 488-conjugated antibodies diluted in BSA-PBS was performed for 45 min at 37°C. DNA was stained with Hoechst 33342 (Sigma-Aldrich). After BSA-PBS and PBS washing, coverslips were mounted on slides using Fluoprep mounting medium (bioMérieux). Fluorescence microscopy was done with a Zeiss Axiovert 200 M microscope equipped with a Plan-Apochromat 100ϫ (1.4 numerical aperture) objective, a Zeiss Axiocam digital camera, and Axiovision software, version 4.6. For quantification of L1-7 signals, 10 random images per experiment were taken with identical settings (fixed exposure time and focal plane); the pictures were not deconvoluted and no modifications regarding contrast and brightness were made. Pixel-by-pixel analysis was performed using the Axiovision colocalization module with fixed thresholds for all images. The total number of L1-7 pixels corrected by the total number of DNA (cell nuclei) pixels (L1-7/DNA) was set as the measure for uncoating. Uncoating in control experiments (control siRNA and dimethyl sulfoxide [DMSO]) was set to 100%.
Endocytosis assay. HeLa cells were infected either 48 h after siRNA transfection or before the addition of inhibitor. For immunostaining of cell surface-bound pseudovirions, cells were incubated with anti-L1 (K75) antibody (36) (Fig. 1) . HPV16 infectivity was significantly reduced by the V-ATPase D-specific siRNAs compared to the results for the control siRNA. This demonstrates that a functional V-ATPase is required for successful HPV infection.
V-ATPase is required for uncoating/disassembly of HPV. Next, we analyzed which step of HPV infection is affected by VATPase inhibition. To examine the role of V-ATPase in viral endocytosis, control and V-ATPase D-depleted cells were incubated with HPV16 pseudovirions (PsVs) for 1 or 20 h, and surfaceassociated virions were quantified by flow cytometry using the polyclonal anti-L1 antibody K75 (Fig. 2a) . The decrease of surface-bound particles between 1 and 20 h of infection represents HPV endocytosis. We found that endocytosis of HPV16 particles was not affected in V-ATPase subunit D1 knockdown cells (Fig.  2b) . To analyze the role of V-ATPase in HPV uncoating/disassembly during infection, we examined the amounts of disassembled capsids in endosomes of control and V-ATPase siRNA-transfected cells using the specific anti-L1 monoclonal antibody L1-7, which recognizes an epitope that is located on the inner side of intact capsids and is only accessible after internalization and disassembly of capsids (Fig. 2c) (10, 13, 38, 39 ). Quantitative analysis of fluorescence micrographs revealed a significant inhibition of HPV16 uncoating/disassembly in cells with V-ATPase subunit D1 knockdown (Fig. 2d) .
Saliphenylhalamide inhibits HPV infection. To investigate whether HPV infection can be blocked by a small molecule inhibitor of V-ATPase, we quantified the effects of saliphenylhalamide (SaliPhe), a specific V-ATPase inhibitor, against low-risk HPV6 and -11, as well as high-risk HPV16, -18, and -31 (Fig. 3) subtypes, the SI values were 2.6 for HPV16, 3.7 for HPV18, and 4.5 for HPV31. Similar to siRNA knockdown, inhibition of V-ATPase with SaliPhe did not impair endocytosis of HPV16 PsVs but it significantly reduced uncoating of HPV16 PsVs (Fig. 4) .
Effects of other V-ATPase inhibitors on HPV infection. Derivatives of salicylihalamide A and other specific V-ATPase inhibitors were screened against high-risk HPV subtypes 16, 18 , and 31 to analyze whether small modifications on the side chain or on the backbone could improve selectivity or reveal pharmacological differences between the three subtypes (see Tables S1 and S2 in the supplemental material). Compound 543229, which shares similarities with enamides but does not contain a functional enamide side chain, was included as a negative control. As expected, 543229 did not show an anti-HPV or cytotoxic effect at concentrations up to 50 M. The lowest EC 50 s were observed for concanamycin A against HPV31 (0.138 nM), while SL-2073 was ineffective against all HPV subtypes at concentrations up to 50 M. The EC 50 s determined for the different compounds were similar for the three HPV types. The CC 50 values, as a read-out of cytotoxicity, were measured after a 5-day incubation of cells with inhibitors. The 5-day cytotoxicity is particularly strict to also account for longer treatment durations. The lowest CC 50 value was obtained for concanamycin A with 0.19 nM, and the highest for SL-2036 with 18.39 M. The EC 50 and CC 50 values of macrolactone V-ATPase inhibitors were in the subnanomolar range, except for ApiOpen, which had EC 50 s of around 30 nM, indicating that the transannular oxygen that is absent in ApiOpen compared to ApiA has a role in the antiviral and cytotoxic effects.
To compare all compounds with respect to cytotoxicity and anti-HPV effect, SIs are shown in Table S1 in the supplemental material. SI values above 1 indicate an antiviral effect distinct from cytotoxic effects. For the compounds tested, the SI values ranged from 0.002 for SL-3177 to 11 for SaliPhe. While the SI values differed substantially between compounds, the SI values between the three HPV types were comparable for a given compound. LX-1231, SL-2072, and SL-3175 had SI values below 1 and were ineffective against HPV. ArchB had an SI value of about 1. All other compounds were considered active.
Effects of selected V-ATPase inhibitors on HPV in HaCaT and NHEK cells. To validate our results in more relevant cell types, we tested some selected inhibitors in HaCaT cells, an immortalized human keratinocyte cell line and, more importantly, in normal human epithelial (NHEK) cells, primary keratinocytes which constitute the natural target cells of HPV infection (Fig. 5) .
We observed that the EC 50 s, as well as the CC 50 s, were increased in HaCaT cells compared to the values in HeLa cells (Fig.  5a to c) SaliPhe, which had the best SI in HaCaT cells, was also tested in NHEK cells (Fig. 5d) . Therefore, NHEK cells were infected for 48 h with HPV16 PsVs in the presence of serial dilutions of SaliPhe. The resulting EC 50 and CC 50 were 0.12 M and 7.2 M, respectively. This gives an SI of 60, indicative of a strong HPV16 infec- tion inhibitory potency at low cytotoxicity for SaliPhe in NHEK cells.
DISCUSSION
We report here the functional requirement of V-ATPase for HPV infection and provide a comparison of different V-ATPase inhibitors with respect to their anti-HPV activities. We show that endocytosis of HPV particles was not affected by V-ATPase inhibition but that capsid disassembly/uncoating within the endosomal compartment was strongly dependent on V-ATPase activity. This finding can be pharmacologically exploited to prevent HPV infection by using small molecule V-ATPase inhibitors. Interestingly, not all V-ATPase inhibitors tested in this study were pharmacologically active (SI Ͻ 1); however, the majority of inhibitors that proved to be active were equally effective against different HPV subtypes. This is indicative of broad-spectrum anti-HPV activity of this group of compounds. Although the SI seems low, VATPase inhibitors may nevertheless have some merit when combined with other inhibitors applied, for instance, as lubricants or vaginal gels to build up a cascade of several steps for prevention of sexually transmitted viral infections, including HPV.
Antiviral compounds that inhibit the early steps of HPV infection represent an attractive alternative for HPV prevention, as vaccines do not yet confer full protection against all high-risk HPV types and might be too expensive for general use in some countries. Hence, chemoprevention of HPV infection might be an interesting prophylactic approach to prevent sexual transmission of HPVs. Besides V-ATPase inhibitors, several other HPV antivirals inhibiting different steps of early HPV infection have already been described. Primary attachment of HPV particles to target cells can be inhibited by carrageenans (40) , which opsonize the virions by covering the surface and thus inhibit attachment to target cells, or by cationic polymers, such as polyethylenimine (41) , which block the primary receptors on the cell surface. DSTP27, a derivative of dispirotripiperazine, also inhibits primary HPV-cell interaction when administered prior to infection. When administered postattachment, this molecule directs virions into a noninfectious internalization pathway (12) . A recent screen of a small-compound library has identified new antiviral molecules that inhibit a notyet-defined postentry step of HPV infection (42) . In the same line, lately a genome-wide siRNA screen has identified the retromer as a cellular factor required for HPV infection and shown that Retro-2, a small molecule inhibitor of retrograde transport, inhibits HPV16 infection (43) . Interestingly, in the same screen, VATPase was also identified as a cellular factor necessary for HPV infection, confirming our report. As the HPV inhibitors described above act on different steps of infection, combinations of these molecules could be used in formulations, such as lubricants, for application in the anogenital area to confer multiple layers of protection against HPV.
In conclusion, we show for the first time that the vacuolar ATPase is involved in the viral uncoating step during papillomavirus infection. V-ATPase inhibitors seem to have broad-spectrum anti-HPV activity, providing new pharmacological opportunities.
